inhibitor

(redirected from alpha1-proteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
GLASSIA[TM], which was approved by the FDA on July 1, 2010, is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency.
Glassia(TM) is a unique, high purity, liquid, ready-to-use liquid Alpha- 1-Proteinase Inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor, also known as Alpha1-Antitrypsin Deficiency.
The effect of augmentation therapy with any alpha1-proteinase inhibitor (A1PI) on pulmonary exacerbations and on the progression of emphysema in AAT deficiency has not been demonstrated in randomized, controlled clinical trials.
Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency.
CSL Behring is the maker of Alpha1-Proteinase Inhibitor (Human), Zemaira(R), which is indicated for chronic augmentation and maintenance therapy for individuals with established AAT deficiency and clinical evidence of emphysema.